<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543658</url>
  </required_header>
  <id_info>
    <org_study_id>The first affiliated hospital</org_study_id>
    <nct_id>NCT02543658</nct_id>
  </id_info>
  <brief_title>Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension</brief_title>
  <official_title>The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Nanchang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis with Intra-abdominal Hypertension have high mortality rate,
      intra-abdominal pressure mainly because of intestinal paralysis which due to edema,
      intestinal gas, fluid and other intestinal dysfunction.Neostigmine is an anti-cholinesterase
      drugs, can enhance intestinal peristalsis, promote flatus, defecation. This study will
      determine the efficacy of neostigmine in the treatment of acute pancreatitis with
      Intra-abdominal Hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of acute pancreatitis with Intra-abdominal hypertension still no ideal method.
      At present, through fasting, fluid resuscitation, prevention of shock, to correct acid-base
      balance and electrolyte imbalance, acid suppression, inhibition of pancreatic secretion,
      rational use of antibiotics and other general of conservative treatment, such as the failure
      of conservative treatment may be open decompression surgery, but trauma, and high mortality.
      Therefore an urgent need to explore and establish effective treatment IAH and Abdominal
      compartment syndrome to improve SAP's cure rate and reduce mortality.

      Neostigmine as an anti-cholinesterase drugs, through acetylcholine in cholinergic
      transmission and cholinesterase competitively binding site, inhibiting the hydrolysis of
      acetylcholine, enhance and strengthen the role of cholinergic excitatory parasympathetic
      activity , restore the patient's bowel movements, so that the body showed a muscarinic
      (M-like) effect. When gastrointestinal M receptor stimulant can enhance intestinal
      peristalsis, promote flatus, defecation.

      The investigators observed neostigmine can effectively promote intestinal gas, fluid
      emptying, thereby reducing intra-abdominal pressure. Therefore, prospective studies are
      needed to clearly worth neostigmine in the treatment of acute pancreatitis with IAH efficacy
      and safety.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of intra-abdominal pressure From admission to seventh days</measure>
    <time_frame>From admission to seventh days,Measured once every 6 hours</time_frame>
    <description>Drug use for 7 days,Through the Bladder pressure measurement reaction intra-abdominal pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal motility and intestinal emptying function</measure>
    <time_frame>From admission to seventh days</time_frame>
    <description>Drug use for 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of abdominal compartment syndrome</measure>
    <time_frame>From admission to seventh days</time_frame>
    <description>Drug use for 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of organ failure</measure>
    <time_frame>From admission to seventh days</time_frame>
    <description>Drug use for 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From admission to seventh days</time_frame>
    <description>Drug use for 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events during treatment</measure>
    <time_frame>From admission to seventh days</time_frame>
    <description>Drug use for 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the recurrence rate of Intra-abdominal hypertension</measure>
    <time_frame>From admission to seventh days</time_frame>
    <description>Drug use for 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Security of Neostigmine</measure>
    <time_frame>From admission to seventh days</time_frame>
    <description>Drug use for 7 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Pancreatitis</condition>
  <condition>Intra-abdominal Hypertension</condition>
  <arm_group>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of neostigmine combined the traditional treatment of Acute Pancreatitis combined with Intra-abdominal Hypertension according to the associated guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The traditional treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The traditional treatment of Acute Pancreatitis combined with Intra-abdominal Hypertension according to the associated guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Intramuscular injection of neostigmine</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <other_name>proserine</other_name>
    <other_name>prostigmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The traditional treatment</intervention_name>
    <description>the traditional treatments according to associated guidelines</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_label>The traditional treatment</arm_group_label>
    <other_name>Conventional drugs according to the guideline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet the diagnostic criteria for diagnosis and treatment of acute pancreatitis in 2013
             Chinese guide acute pancreatitis;

          2. According to the diagnostic standard of intra-abdominal hypertension of World Society
             of the Abdominal Compartment Syndrome;

          3. IAH I level or above;

          4. IAH belong to the bloating, or at the same time, but by puncture drainage fluid after
             intra-abdominal hypertension and Abdominal compartment syndrome treatment is invalid;

          5. Age 18-70 one full year of life;

          6. Onset of pancreatitis within &lt;=2 weeks;

          7. And signed the informed consent of patients.

        Exclusion Criteria:

          1. Mechanical intestinal obstruction patients;

          2. Neostigmine taboo subjects;

          3. Ming or mannitol allergic patients of neostigmine;

          4. Refused to sign the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nonghua Lv, MD</last_name>
    <role>Study Chair</role>
    <affiliation>the Frist Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wen hua He, MD</last_name>
    <phone>13879182642</phone>
    <email>hewenhua@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling yu Luo, MD</last_name>
    <phone>15270855639</phone>
    <email>15270855639@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nonghua Lv, MD</last_name>
      <phone>13707086809</phone>
      <email>lunonghua@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Kunhe Zhang, MD</last_name>
      <phone>13007202818</phone>
      <email>393467260@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nonghua Lv, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25.</citation>
    <PMID>23100216</PMID>
  </reference>
  <reference>
    <citation>Mifkovic A, Skultety J, Sykora P, Prochotsky A, Okolicany R. Intra-abdominal hypertension and acute pancreatitis. Bratisl Lek Listy. 2013;114(3):166-71. Review.</citation>
    <PMID>23406186</PMID>
  </reference>
  <reference>
    <citation>Sugrue M, Jones F, Deane SA, Bishop G, Bauman A, Hillman K. Intra-abdominal hypertension is an independent cause of postoperative renal impairment. Arch Surg. 1999 Oct;134(10):1082-5.</citation>
    <PMID>10522851</PMID>
  </reference>
  <reference>
    <citation>Vidal MG, Ruiz Weisser J, Gonzalez F, Toro MA, Loudet C, Balasini C, Canales H, Reina R, Estenssoro E. Incidence and clinical effects of intra-abdominal hypertension in critically ill patients. Crit Care Med. 2008 Jun;36(6):1823-31. doi: 10.1097/CCM.0b013e31817c7a4d.</citation>
    <PMID>18520642</PMID>
  </reference>
  <reference>
    <citation>Kasi PM. The use of intravenous neostigmine in palliation of severe ileus. Case Rep Gastrointest Med. 2013;2013:796739. doi: 10.1155/2013/796739. Epub 2013 Feb 14.</citation>
    <PMID>23476830</PMID>
  </reference>
  <reference>
    <citation>Chan B, Whyte I, Dawson A, Downes M. Use of neostigmine for the management of drug induced ileus in severe poisonings. J Med Toxicol. 2005 Dec;1(1):18-22.</citation>
    <PMID>18072098</PMID>
  </reference>
  <reference>
    <citation>Tracey KJ. The inflammatory reflex. Nature. 2002 Dec 19-26;420(6917):853-9. Review.</citation>
    <PMID>12490958</PMID>
  </reference>
  <reference>
    <citation>Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000 May 25;405(6785):458-62.</citation>
    <PMID>10839541</PMID>
  </reference>
  <reference>
    <citation>Schneider L, Jabrailova B, Soliman H, Hofer S, Strobel O, Hackert T, Büchler MW, Werner J. Pharmacological cholinergic stimulation as a therapeutic tool in experimental necrotizing pancreatitis. Pancreas. 2014 Jan;43(1):41-6. doi: 10.1097/MPA.0b013e3182a85c21.</citation>
    <PMID>24212240</PMID>
  </reference>
  <reference>
    <citation>Shaikh N, Kettern MA, Hanssens Y, Elshafie SS, Louon A. A rare and unsuspected complication of Clostridium difficile infection. Intensive Care Med. 2008 May;34(5):963-6. Epub 2007 Nov 20.</citation>
    <PMID>18026931</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>September 4, 2015</last_update_submitted>
  <last_update_submitted_qc>September 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Nanchang University</investigator_affiliation>
    <investigator_full_name>Lingyu Luo</investigator_full_name>
    <investigator_title>Physician-in-charge</investigator_title>
  </responsible_party>
  <keyword>Acute Pancreatitis</keyword>
  <keyword>Intra-abdominal hypertension</keyword>
  <keyword>Abdominal compartment syndrome</keyword>
  <keyword>Curative Effect</keyword>
  <keyword>Security</keyword>
  <keyword>Neostigmine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Intra-Abdominal Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

